Sugi Predict

Sugi Predict / Compounds / SCHEMBL4949482

SCHEMBL4949482

SCHEMBL4949482

Oc1cc2cc(Br)ccc2[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 1/20 0.52
▸ CYP2A6 P11509 1/20 0.47
▸ AHR P35869 1/20 0.47
▸ NR4A2 P43354 1/20 0.47
▸ FLT3 P36888 1/20 0.45
▸ NOS1 P29475 1/20 0.44
▸ METAP2 P50579 1/20 0.44
▸ CSNK2A1 P68400 1/20 0.44
▸ HRH4 Q9H3N8 1/20 0.43
▸ HRH3 Q9Y5N1 1/20 0.43
▸ AR P10275 1/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ IDO1 P14902 2/20 0.39
▸ BCAT1 P54687 1/20 0.39
▸ HDAC3 O15379 1/20 0.38
▸ HDAC4 P56524 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC7 Q8WUI4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2490392 0.83 AHR (0.47) CYP2A6AHRNR4A2NOS1METAP2
SCHEMBL32666155 0.77 FLT3 (0.59) FLT3HRH4
SCHEMBL2454392 0.77 FLT3 (0.59) FLT3HRH4
SCHEMBL21812417 0.77 CYP19A1 (0.55) CYP19A1CYP2A6AHRNR4A2FLT3
SCHEMBL17422783 0.77 CYP19A1 (0.71) CYP19A1CYP2A6AHRNR4A2FLT3
SCHEMBL15690660 0.76 DAO (0.64) CYP19A1FLT3HRH4HRH3
SCHEMBL2486296 0.76 CYP19A1 (0.53) CYP19A1CYP2A6AHRNR4A2FLT3
SCHEMBL903388 0.75 CYP19A1 (0.57) CYP19A1CYP2A6AHRNR4A2FLT3
SCHEMBL8740607 0.74 DAO (0.61) CYP19A1AHRNR4A2FLT3NOS1
SCHEMBL11436421 0.74 DAO (0.61) AHRFLT3HRH4IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4737455-A1 COMPOUND CONTAINING MULTI-FUSED RING STRUCTURE Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2026-05-06 — — EP disclosed
US-20260098037-A1 COMPOUND CONTAINING MULTI-FUSED RING STRUCTURE CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2026-04-09 — — US disclosed
EP-3099667-B1 ANTAGONISTS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS FOR THE TREATMENT OF INFLAMMATION ALLERGAN INC (US) 2017-11-01 — — EP disclosed
EP-2910547-B1 COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG UNIV OKAYAMA (JP) 2017-06-14 — — EP disclosed
US-9657018-B2 Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation ALLERGAN, INC. (US) 2017-05-23 — — US disclosed
US-20170096423-A1 ANTAGONISTS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS FOR THE TREATMENT OF INFLAMMATION ALLERGAN, INC. 2017-04-06 — — US disclosed
EP-3099667-A1 ANTAGONISTS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS FOR THE TREATMENT OF INFLAMMATION ALLERGAN, INC. (US) 2016-12-07 — — EP disclosed
US-9512075-B2 Compound; tautomer and geometric isomer thereof; salt of said compound, tautomer, or geometric isomer; method for manufacturing said compound, tautomer, isomer, or salt; antimicrobial agent; and anti-infective drug OKAYAMA UNIVERSITY (JP) 2016-12-06 — — US disclosed
CN-104159901-B Triazolopyridine oxazine derivatives 默克专利股份公司 2016-10-26 — — CN disclosed
US-9365569-B2 Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation ALLERGAN, INC. (US) 2016-06-14 — — US disclosed
CN-1250526-C Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN INC (US) 2006-04-12 — — CN disclosed
CN-1541098-A Combination therapy for treatment of cancer �ո��� 2004-10-27 — — CN disclosed
CN-1311775-A Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN INC (US) 2001-09-05 — — CN disclosed
CN-1008733-B Be used as the preparation of 2-oxyindole-1-methane amide that the 3-of anodyne and antiphlogistic replaces PFIZER (US) 1990-07-11 — — CN disclosed
CN-1007428-B PROCESS FOR MAKING 2-OXINDOLE-1-CARBOXAMIDES AND INTERMEDIATES THEREFOR PFIZER (US) 1990-04-04 — — CN disclosed
CN-1003855-B Process for preparing 1, 3-disubstituted 2-oxindoles 美国辉瑞有限公司 1989-04-12 — — CN disclosed
CN-85101795-A With 1, the two 2-oxyindoles that replace of 3-prepare pain killer and antiphlogistic — 1987-04-08 — — CN disclosed
CN-85103527-A Preparation N, the method for the disubstituted 2-hydroxyindole of 3--1-hydroxyalkyl cooh amide — 1987-01-28 — — CN disclosed
CN-85101029-A The method of preparation-2-oxyindole-1-methane amide and intermediate product thereof — 1987-01-24 — — CN disclosed
CN-85101028-A Be used as the preparation of 2-oxyindole-1-methane amide that the 3-of anodyne and antiphlogistic replaces — 1987-01-17 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098037-A1 COMPOUND CONTAINING MULTI-FUSED RING STRUCTURE SLC5A2, SLC5A11, SLC5A1 CYP19A1 692/4885CYP2A6 921/4885AHR 3255/4885
US-20170096423-A1 ANTAGONISTS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS FOR THE TREATMENT OF INFLAMMATION PTGER1, PTGER4, PTGER2 CYP19A1 3342/4885CYP2A6 1441/4885AHR 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.